SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wednesday's Economic News Crunch Could Tilt Markets
- The Social Media Gaming Threat
- Obama Reiterates Commitment to Boost US-India Ties
- NBA D-League On The Rise
- Japan Export Rebound Eases Fear of New Recession
- Australia Wheat Exporters Face Challenges: GrainCorp
- Stifling Anger at Work Can Kill, Survey Finds
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- Sales of New Homes Forecast to Rise 2%
- Americans Ditch Planes for Trains this Thanksgiving
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- Starbucks Eyes China as Next Major Market
- Citi Mortgage Reveals Something the US Treasury Won't
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
![]() |
Johnson & Johnson [JNJ
Loading...
()
] is buying Omrix Biopharmaceuticals[OMRI
Loading...
()
] for $438 million in cash. And Bristol-Myers Squibb [BMY
Loading...
()
] has moved forward on an option to buy into an experimental drug at Exelixis (EXEL), entitling the baby biotech to a $20 million cash payment from BMY.
Genentech [DNA
Loading...
()
] announced positive results from a big study on Avastin for breast cancer. The biotech giant hopes to use the data to win full out FDA approval of the drug for that type of cancer.
Meantime, mark December 4th on your calendar. Dow component Merck [MRK
Loading...
()
] announced this morning that's when it will hold a conference call to provide new financial guidance. It's become standard operating procedure for the drugmaker to do that a week ahead of its analyst/investor meeting.
Coincidentally, or maybe not, MRK's cholesterol drug partner Schering-Plough[SGP
Loading...
()
] is holding its Research and Development Day with Wall Street today. In his opening remarks Chairman and CEO Fred Hassan, among many other things, touched on the economy. "Our sector is more resilient than most, but we're not immune," he said. I'm at the company's HQ in Kenilworth, NJ to do a live interview with Hassan around 1:30 pm ET on "Power Lunch."
Finally, a note about the front-page article about Pfizer's [PFE
Loading...
()
] Viagra for athletes in "The New York Times" on Sunday. It's a good "talk about" story for the water-cooler, but will have little, if any, material impact on Viagra sales.
Far down in the piece it mentioned side effects including "priapism." But the reporter/editors apparently assumed readers would know what that means. It's the side effect rattled off in impotence drug commercials that often draws chuckles and provides comedians with stand-up routine material about erections lasting four hours or more.
Questions? Comments?









